Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14530950 | 0.90 | SMN1; SMN2 (0.46) | ACHESMN1; SMN2EPHX1 | |
| SCHEMBL12010828 | 0.83 | ACHE (0.42) | ACHEHRH3 | |
| SCHEMBL19652092 | 0.83 | EGLN1 (0.39) | ACHESMN1; SMN2EGLN1CHRM3EPHX1 | |
| SCHEMBL23560059 | 0.80 | ACHE (0.42) | ACHESMN1; SMN2EPHX1 | |
| SCHEMBL10238597 | 0.78 | SMN1; SMN2 (0.34) | SMN1; SMN2EGLN1CHRM3HRH3EPHX1 | |
| SCHEMBL9477536 | 0.77 | ACHE (0.69) | ACHE | |
| SCHEMBL19658593 | 0.77 | ACHE (0.62) | ACHESMN1; SMN2 | |
| SCHEMBL17888287 | 0.76 | EGLN1 (0.49) | ACHEEGLN1HRH3 | |
| SCHEMBL5754421 | 0.76 | DPP4 (0.42) | SMN1; SMN2EGLN1CHRM3HRH3CHRM2 | |
| SCHEMBL14155733 | 0.76 | LTA4H (0.44) | SMN1; SMN2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | ACHE 2649/4885SMN1; SMN2 1221/4885EGLN1 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.